

LPL - PRODUCTION TEST COLLECTION CENTRE SECTOR - 18, BLOCK-E ROHINI DELHI 110085

Lab No. : DUMMYS312 Age: 25 Years Gender: Male Reported : 4/6/2021 2:30:19PM

A/c Status : P Ref By : DR. DUMMY DUMMY Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
AUTOIMMUNE LIVER DISEASES PROFILE IgG (Immunoblot)	*		X
AMA-M2 Antibody	Negative		Negative
M2-3E (BPO) Antibody	Negative		Negative
Sp100 Antibody	Negative		Negative
PML Antibody	Negative	0,5	Negative
gp210 Antibody	Negative		Negative
LKM-1 Antibody	Negative		Negative
LC-1 Antibody	Negative		Negative
SLA/LP Antibody	Negative		Negative
Ro-52 Antibody	Negative		Negative

Note

- 1. It is recommended to confirm all positive results by Monospecific tests.
- 2. Autoimmune reactivities are not by themselves diagnostic, but must be correlated with other laboratory & clinical findings.
- 3. Test conducted on Serum.

Comments

Autoimmune liver diseases (AiLD) encompass the following diseases: Autoimmune hepatitis (AIH), Primary biliary cirrhosis (PBC) & Primary sclerosing cholangiitis (PSC). In addition, so-called Overlap syndromes can occur, i.e. the simultaneous presence of two different AiLD or one AiLD in combination with another autoimmune disease, for example Systemic sclerosis (SSc). Autoimmune hepatitis (AIH) is further divided into two subtypes namely, AIH type 1 and AIH type 2.

* Not in NABL scope



Page 1 of 3



LPL - PRODUCTION TEST COLLECTION CENTRE SECTOR - 18, BLOCK-E ROHINI DELHI 110085

Name : DUMMY Collected : 4/6/2021 11:18:00AM

Lab No. : DUMMYS312 Age: 25 Years Gender: Male Reported : 4/6/2021 11:22:53AM Reported : 4/6/2021 2:30:19PM

A/c Status : P Ref By : DR. DUMMY DUMMY Report Status : Final

Test Name Results Units Bio. Ref. Interval

Prevalence of various autoantibodies in Autoimmune liver diseases

Autoantibodies	 Prevalence in AIH	Prevalence in PBC	Prevalence in PSC	Prevalence in Overlap syndrome
ANA	40% - 60% (AIH)			
100% (AIH - type 1)	5% - 50%	6% - 35%	5% - 100 %	
dsDNA	20% - 30%			
ASMA	40% - 50% (AIH)			
60% - 90% (AIH - type 1)	25% - 50%	<10%		
SLA/LP	15% - 30% (Europe, North America) 7% (Japan)			<10%
Ro-52	5% - 19%	<5%		<10%
LC-1	10% (AIH)			
35% (AIH - type 2)			 	
LKM-1	3% - 5% (AIH)	Y 		
70% (AIH - type 2)		 	 	
AMA		85% - 95%	<5%	30% - 96%
M2-3E (BPO)	4%	90% - 95%		
Sp100	1/>	15% - 31%		
PML	4%	13%		
gp210	<mark>-</mark> 4 <mark>%</mark>	26%		
Cenp		10% - 25%		
P-ANCA	10%	6% - 28%	40% - 50%	



^{*} Not in NABL scope



LPL - PRODUCTION TEST COLLECTION CENTRE **SECTOR - 18, BLOCK-E ROHINI DELHI 110085**

Name **DUMMY** Collected

: 4/6/2021 11:18:00AM

Lab No.

DUMMYS312 Age: 25 Years

Received Reported : 4/6/2021 11:22:53AM

Male

: 4/6/2021 2:30:19PM

Ref By: DR. DUMMY DUMMY A/c Status

Report Status : Final

Test Name

Gender:

Units

Bio. Ref. Interval

Dr. Ajay Gupta MD, Pathology HOD Hematology & Immunohematology

NRL - Dr Lal PathLabs Ltd

Dr.Sarita Kumari Lal MD, Pathology Consultant Pathologist

Dr Lal PathLabs Ltd

Dr Sunanda MD, Pathology Consultant Pathologist Dr Lal PathLabs Ltd

----End of report ---

IMPORTANT INSTRUCTIONS

*Test results released pertain to the specimen submitted.*All test results are dep<mark>endent on</mark> the quality of the sample received by the Laboratory *Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit request within 72 hours post reporting.*Test results may s<mark>how inte</mark>rlaboratory variations.*The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. *Contact customer care Tel No. +91-11-39885050 for all queries related to test results. (#) Sample drawn from outside source.

* Not in NABL scope



Page 3 of 3